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CASE REPORT
Chronic hepatitis C virus (HCV) infection is a
major cause of chronic liver disease, which can
lead to cirrhosis and hepatocellular carcinoma.
Therefore, efficient antiviral treatment for HCV
has long been needed. Recently, the most impor-
tant advance in the treatment of hepatitis C has
been the development of a long-acting inter-
feron (IFN), or pegylated IFN, which is produced
by covalent attachment of polyethylene glycol to
the IFN molecule.1 Combination therapy with
pegylated IFN-alfa and ribavirin has become the
optimal choice of therapy for chronic hepatitis
C, as recommended by the American Association
for the Study of Liver Disease in 2004.2
Nevertheless, pegylated IFN-alfa and ribavirin
combination therapy for chronic hepatitis C pro-
duces a number of side effects that are dominated
by fatigue, influenza-like symptoms, hematolog-
ical abnormalities, and neuropsychiatric symp-
toms.3 Pulmonary toxicity, including sarcoidosis,
interstitial pneumonitis and bronchiolitis oblit-
erans organizing pneumonia, occurs rarely and
develops after a long period of treatment.4–6 In
general, the adverse effects are dose- and duration-
dependent; thus, most of them are managed safely
and effectively by dose reduction.3 Management
of infrequently reported events, such as tubercu-
losis (TB), remains controversial. However, once
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Successful Antiviral and Antituberculosis
Treatment With Pegylated Interferon-alfa and
Ribavirin in a Chronic Hepatitis C Patient
With Pulmonary Tuberculosis
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Pulmonary tuberculosis is a rare side effect of antiviral treatment for chronic hepatitis C. We present the
case of 55-year-old woman with chronic hepatitis C, who developed pulmonary tuberculosis after receiv-
ing 8 weeks of peginterferon alfa-2a plus ribavirin therapy. Antituberculous treatment was started and an-
tiviral agents were given continually at adjusted doses. Her symptoms of cough with blood-tinged sputum
improved 1 month after antituberculous therapy. Treatment for hepatitis C and pulmonary tuberculosis
were completed after 6 months. At 6 months after antiviral therapy, a sustained virological response was
achieved and follow-up chest radiography showed a marked regressive change. This is believed to be the
first case report of complete remission from hepatitis C and pulmonary tuberculosis treated concurrently
with antiviral and antituberculous agents. [J Formos Med Assoc 2009;108(9):746–750]
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a serious adverse event occurs, which has the 
potential to cause significant morbidity and end-
organ damage, therapy should be withdrawn 
immediately.
Here, we report successful concurrent antiviral
and antituberculous therapy in a patient with
chronic hepatitis C who developed pulmonary TB
during pegylated IFN alfa-2a plus ribavirin therapy,
accompanied by HCV eradication and regression
of pulmonary TB.
Case Report
A 55-year-old Taiwanese woman who had chronic
HCV infection that lasted for several years was
followed-up regularly at a local medical clinic. In
April 2006, she was referred to our outpatient
department because of persistent elevation of
transaminases. She had a history of type 2 diabetes
that was controlled by oral antidiabetic therapy.
Laboratory analyses revealed the following: as-
partate transaminase (AST), 112 U/L; alanine
transaminase (ALT), 108 U/L; total bilirubin,
1.4 mg/dL; white blood cell count, 4500/mm3;
neutrophil count, 2835/mm3; and lymphocyte
count, 1305/mm3. Virological testing was positive
for anti-HCV antibody, as assessed using third-
generation ELISA (Ax SYM HCV 3.0; Abbott 
Laboratories, Chicago, IL, USA). HCV RNA deter-
mined by a standardized, qualitative reverse
transcriptase polymerase chain reaction was pos-
itive (Amplicor; Roche Diagnostics, Branchburg,
NJ, USA), and genotyping of HCV was 2a/2c by
using reverse hybridization assay (Inno-LiPA HCV
II; Innogenetics NV, Gent, Belgium). All serum
markers for hepatitis B virus produced negative
results. Liver echo revealed cirrhosis. Echo-guided
liver biopsy demonstrated chronic active hepati-
tis with moderate activity and cirrhosis based on
modified Knodell histology index.
Combination therapy with pegylated IFN
alfa-2a 180μg weekly subcutaneously and ribavirin
1000 mg/day orally was initiated on May 15, 2006.
She began to suffer from cough with blood-tinged
phlegm in July 2006, 8 weeks after treatment
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Figure 1. (A) Screening chest radiography 2 years before
antiviral treatment shows a patchy density over the right
upper lobe (RUL). (B) Eight weeks after antiviral treatment,
chest radiography shows a cavitary lesion with mixed alve-
olar and interstitial infiltration over the RUL. (C) After com-
pletion of treatment for pulmonary tuberculosis, chest
radiography shows a marked regressive change over the
RUL as compared with that in (B).
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started. Crepitant rales were audible on ausculta-
tion over the right upper lobe of the lung. Chest
radiography (Figure 1B) showed a cavitary lesion
and mixed alveolar and interstitial infiltration
over the right upper lobe. A review of chest radi-
ography at a screening performed on December
2004 found a patchy density over the same 
pulmonary area (Figure 1A), which was highly
suggestive of TB reactivation. Sputum culture
was positive for Mycobacterium tuberculosis, which
was susceptible to all tested antimicrobial agents.
Anti-TB therapy with rifampicin (450 mg/
day), isoniazid (300 mg/day) and ethambutol
(1200 mg/day), together with pyridoxine was
started on July 21, 2006. Meanwhile, pegylated
IFN alfa-2a and ribavirin were given continually
at adjusted doses. After 1 month of anti-TB treat-
ment, the symptom of cough with blood-tinged
sputum improved. At the end of HCV treatment,
the patient achieved a biochemical and viro-
logical response (normal ALT and negative HCV
RNA). The ALT levels decreased gradually and
normalized 6 weeks after antiviral therapy, and
were persistently normal during antituberculous
treatment. At 6 months after antiviral therapy, a
sustained virological response (SVR) was achieved.
In addition, the treatment for pulmonary TB was
carried out for 6 months (from July 2006 to
January 2007). Repeated sputum cultures for 
M. tuberculosis were negative in three consecutive
samples, and follow-up chest radiography showed
a marked regressive change (Figure 1C). Details
of the clinical course, neutrophil and lympho-
cyte counts, and ALT levels are shown in Figure 2.
Discussion
Over the past few years, the global burden of TB
has been increasing despite the availability of 
effective treatment.7 Human immunodeficiency
virus (HIV) infection is considered to be the most
potent risk factor for the resurgence of TB. More-
over, a recent, large, case-controlled trial demon-
strated that chronic hepatitis C patients had a
significantly higher prevalence of TB infection
compared with control subjects (3.3% vs. 1.3%)
in the United States.8 After excluding potentially
immunocompromised patients, including those
with HIV, organ transplant, and cirrhosis, HCV
remained significantly associated with TB infec-
tion. In Taiwan, there has been a gradual rise in
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Figure 2. Clinical course and laboratory data of the patient with chronic hepatitis C who developed pulmonary tuberculosis
during pegylated interferon alfa-2a plus ribavirin therapy. Peg-IFN=pegylated interferon; RIF= rifampicin; INH= isoniazid;
EMB = ethambutol; ALT = alanine transaminase.
the annual incidence of TB in recent decades, 
following a transient decrease in the 1970s; the
highest incidence was in the 1950s and 1960s.9
Thus, in Taiwan, a TB endemic area, patients with
chronic hepatitis C may have co-infection with TB.
Careful evaluation of clinical history and control
chest radiography should be taken into account
before the initiation of IFN-based antiviral ther-
apy. Our patient developed pulmonary TB after
receiving 8 weeks of peginterferon alfa-2a plus
ribavirin therapy. A major possibility was reacti-
vation of pulmonary TB during antiviral therapy.
However, the possibility of unrecognized reacti-
vation of TB before antiviral therapy could not
be excluded because pretreatment chest radiog-
raphy was performed, although there were no
obvious respiratory symptoms and signs before
initiation of treatment.
The causative role of IFN-based antiviral ther-
apy in exacerbating TB infection remains contro-
versial, and the possible mechanisms are as yet
unclear. IFN-alfa is a cytokine with immunomod-
ulatory actions, which is produced by many cell
types including T cells, B cells, fibroblasts, mac-
rophages and endothelial cells.1 Its effect includes
antiviral activity, growth regulation, regulation of
cell differentiation, and enhancement of the ac-
tivity of natural killer cells and cytotoxic T lym-
phocytes. It is likely that IFN-alfa prompts the
reactivation of latent TB or other opportunistic
infections because of the frequent side effect of
leukopenia–neutropenia.3,10,11 In particular, a de-
cline in CD4 count in patients treated with IFN-
alfa leads to reactivation of latent infection rather
than the development of primary infection.10,11
Previous reports have demonstrated that infection
such as herpes simplex, upper respiratory tract
infection, bronchitis, oral candidiasis, skin infec-
tion, pneumonia, otitis externa, and endocarditis
may occur during IFN or pegylated IFN plus rib-
avirin therapy for chronic hepatitis C.12,13 On the
contrary, other clinical findings have shown a
possible protective effect of IFN-alfa on TB exac-
erbation. In a report by Nahon et al, a patient
undergoing treatment for hepatitis C experi-
enced TB exacerbation after completing antiviral
therapy.14 Although onset of symptoms (fever,
cough and radiological chest abnormalities) had
occurred during treatment, the clinical progres-
sion became apparent 1 month after treatment
completion.
A review of English-language publications on
MEDLINE up to 2007 shows that three cases of
reactivated TB have been documented to be asso-
ciated with pegylated-IFN alfa plus ribavirin ther-
apy for chronic hepatitis C.10,11,15 One report
described a patient coinfected with HCV and
HIV, who was diagnosed with TB adenitis after
receiving 12 weeks of pegylated IFN-alfa plus riba-
virin therapy.11 The other two patients developed
pulmonary TB after 6 weeks and 7 months of pe-
gylated IFN-alfa plus ribavirin therapy, respec-
tively. Among the three cases, TB was treated
successfully without complications.10,15 However,
two patients discontinued the antiviral therapy
at 6 and 12 weeks, respectively, and the other one
completed the provisional period of 12 months
without mentioning whether a SVR was achieved.
Unlike the three previously reported cases, our
patient achieved an SVR when developing pul-
monary TB during pegylated-IFN plus ribavirin
therapy for chronic hepatitis C. Concurrent anti-
TB therapy resulted in complete remission of
pulmonary TB. However, our case was genotype
2a/2c, which was easily eradicated, and a 24-week
course of pegylated-IFN plus ribavirin therapy
achieved an 80–90% SVR.16
Drug-induced hepatotoxicity associated with
first-line antituberculous drugs such as isoniazid,
rifampin and pyrazinamide is a well-known ad-
verse effect and may limit their use. Although
chronic liver disease is known to increase the risk
of drug-induced hepatotoxicity, the relative risks
for the various etiologies of chronic liver disease
resulting from development of drug-induced he-
patotoxicity remain unclear. In a study by Kwon
et al,17 22 HCV-seropositive patients (41%) and 19
control subjects (20%) exhibited elevated liver
enzyme levels during anti-TB treatment (p=0.005).
In our case, ALT levels normalized 6 weeks after
antiviral therapy and were persistently normal
during antituberculous treatment. However, 
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careful monitoring of liver function tests is still
necessary in patients who receive combined anti-
viral and anti-TB therapy.
In conclusion, physicians should keep in
mind the possibility of this rare complication
when treating chronic hepatitis C patients with
pegylated IFN-alfa plus ribavirin therapy. Our
case showed successful treatment of reactivation
of pulmonary TB during pegylated IFN-alfa plus
ribavirin therapy for chronic hepatitis C.
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